Kendall Mohler
Corporate Officer/Principal presso ALSP ORCHID ACQUISITION CORPORATION I
Profilo
Kendall M.
Mohler is the founder of Emergent Product Development Seattle, which was founded in 1999.
He held the title of Senior Vice President-Research & Development from 1999 to 2010.
Currently, he is the Managing Director & Chief Development Officer at Accelerator Services Corp.
He is also a Director at Neuvogen, Inc., CSO and SVP at Emergent Product Development Seattle, and Chief Development Officer at ALSP Orchid Acquisition Corp.
I.
Dr. Mohler's former jobs include Vice President-Biological Sciences at Immunex Corp.
from 2001 to 2002, Chief Scientific Officer at ZetaRx Biosciences, Inc., and Senior Vice President-Research at Juno Therapeutics, Inc. from 2015 to 2017.
Dr. Mohler received a doctorate from The University of Texas at Austin and an undergraduate degree from the University of Kansas.
Posizioni attive di Kendall Mohler
| Società | Posizione | Inizio |
|---|---|---|
| ALSP ORCHID ACQUISITION CORPORATION I | Corporate Officer/Principal | - |
Accelerator Services Corp
 Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Corporate Officer/Principal | 01/10/2017 |
| Neuvogen, Inc. | Director/Board Member | - |
Emergent Product Development Seattle
 Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | Private Equity Investor | - |
Precedenti posizioni note di Kendall Mohler
| Società | Posizione | Fine |
|---|---|---|
| JUNO THERAPEUTICS INC | Chief Tech/Sci/R&D Officer | 01/04/2017 |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Corporate Officer/Principal | 01/01/2002 |
ZetaRx Biosciences, Inc.
 ZetaRx Biosciences, Inc. BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., ZetaRx Biosciences, Inc. is a private company that develops therapies for the treatment of cancers and other diseases. The company is based in Seattle, WA. The company was founded by Jack Kavanaugh. ZetaRx Biosciences was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on October 31, 2013 for $8.40 million. | Chief Tech/Sci/R&D Officer | - |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | Founder | - |
Formazione di Kendall Mohler
| The University of Texas at Austin | Doctorate Degree |
| University of Kansas | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 7 |
|---|---|
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
Emergent Product Development Seattle
Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | Health Technology |
ZetaRx Biosciences, Inc.
ZetaRx Biosciences, Inc. BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., ZetaRx Biosciences, Inc. is a private company that develops therapies for the treatment of cancers and other diseases. The company is based in Seattle, WA. The company was founded by Jack Kavanaugh. ZetaRx Biosciences was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on October 31, 2013 for $8.40 million. | Health Technology |
Accelerator Services Corp
Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Finance |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
| Neuvogen, Inc. | |
ALSP Orchid Acquisition Corp. I
 ALSP Orchid Acquisition Corp. I Financial ConglomeratesFinance ALSP Orchid Acquisition Corp. I is a blank check company. It was formed for the purpose of acquiring, through a merger, capital stock exchange, asset acquisition, stock purchase or other similar business combination, one or more operating businesses. The company was founded on August 31, 2021 and is headquartered in Seattle, WA. | Finance |
- Borsa valori
- Insiders
- Kendall Mohler
